Navigation Links
Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine
Date:11/1/2010

Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, New Products & Services Click to view news release full screen  

Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine

 

QUEBEC CITY , Nov. 1 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

The Phase II randomized, placebo controlled clinical trial will evaluate the safety and immunogenicity of different doses of its H5N1 vaccine. Specifically, the vaccine will be studied in approximately 255 healthy adults between the ages of 18 to 60 years. In the first part of the study healthy adults will receive an injection of either a placebo or the H5N1 vaccine at varying doses to determine the optimal dose. In the second part of the study, healthy adults will receive an injection of either a placebo or the H5N1 vaccine at the optimal dose. Interim-results of this study are expected in less than three months.

"The initiation of our Phase II clinical trial is an important step in the development of our plant-based VLP vaccines, which we believe are highly effective, cross-protective, less expensive and faster to produce than current influenza vaccines. It also demonstrates our ability to advance candidates through clinical development," said Andy Sheldon, President and CEO of Medicago. "Our platform is very versatile and to date, we have been able to produce a broad array of other proteins with potential use in the life science industry. This clinical trial therefore provides additional validation for our rapid and cost-effective technology platform offering." About Medicago Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 24, 2010 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.


'/>"/>
SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. Medicago reports positive Phase I results for its avian flu pandemic vaccine
9. Medicago named in Presidential report on meeting the challenges of pandemic influenza
10. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
11. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... During ... connected digital health applications, announced a partnership with Redox, a leader in cloud-based ... to many clinical systems while keeping data secure in the cloud. , The ...
(Date:2/21/2017)... ... February 21, 2017 , ... With ... operational capacity with its strategic internal leadership to provide clients with best ... operational management. With office locations in North Carolina, Massachusetts, Ohio, Illinois, ...
(Date:2/21/2017)... , Feb. 21, 2017   Logicalis Healthcare Solutions ... IT solutions and managed services provider ( www.us.logicalis.com ), ... Desk for Epic. The new service will help hospital ... resources by giving physicians, nurses and other clinicians immediate ... tier-one support. This will allow hospital IT staff to ...
(Date:2/20/2017)... - BioAmber Inc. (NYSE: BIOA ) announced today that Jean-Francois ... the company,s COO, has been named President, effective immediately.  ... Fabrice has overseen the construction, start-up and operation of the manufacturing ... the Mitsui JV.  Fabrice has also been extensively involved in the ... ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):